An ALKi-resistance mutation (I1171T) had been identified in eIMS tumour samples collected following a relapse on crizotinib and again following disease progression during ceritinib treatment.9 However, the resistance mutation was not detected in the eIMS tumour sample which was collected at terminal relapse after prolonged chemotherapy treatment but without an ALK inhibitor. This evidence concerns the gene ALK and neoplasm.